ProQR Therapeutics (PRQR) Competitors $1.86 +0.10 (+5.37%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. NTLA, CRON, REPL, IMTX, GYRE, DAWN, VIR, AVXL, ABUS, and EOLSShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Intellia Therapeutics (NTLA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Intellia Therapeutics Cronos Group Replimune Group Immatics Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus Intellia Therapeutics (NASDAQ:NTLA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the MarketBeat Community prefer NTLA or PRQR? Intellia Therapeutics received 110 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 68.76% of users gave Intellia Therapeutics an outperform vote while only 62.09% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44968.76% Underperform Votes20431.24% ProQR TherapeuticsOutperform Votes33962.09% Underperform Votes20737.91% Do insiders & institutionals believe in NTLA or PRQR? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, NTLA or PRQR? Intellia Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Is NTLA or PRQR more profitable? Intellia Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Intellia Therapeutics' return on equity of -49.34% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% ProQR Therapeutics -134.31%-71.58%-19.70% Does the media refer more to NTLA or PRQR? In the previous week, Intellia Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 10 mentions for Intellia Therapeutics and 7 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.26 beat Intellia Therapeutics' score of 0.66 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NTLA or PRQR? Intellia Therapeutics presently has a consensus target price of $34.95, indicating a potential upside of 307.77%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 328.95%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.67ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better earnings and valuation, NTLA or PRQR? ProQR Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$45.57M19.48-$481.19M-$5.23-1.64ProQR Therapeutics$18.97M10.34-$30.43M-$0.35-5.33 SummaryIntellia Therapeutics beats ProQR Therapeutics on 11 of the 18 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.22M$6.88B$5.60B$8.68BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-5.838.9327.3320.20Price / Sales10.34264.41417.24161.05Price / CashN/A65.8538.2534.64Price / Book3.396.677.124.75Net Income-$30.43M$143.49M$3.23B$247.80M7 Day Performance3.04%5.04%3.59%2.78%1 Month Performance15.84%15.50%13.12%10.13%1 Year Performance1.91%6.19%32.28%15.59% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.9625 of 5 stars$1.87+5.4%$8.00+329.0%-2.2%$196.22M$18.97M-5.83180Positive NewsAnalyst RevisionNTLAIntellia Therapeutics4.6352 of 5 stars$7.16+4.2%$36.75+413.3%-63.6%$741.65M$45.57M-1.32600Analyst RevisionHigh Trading VolumeCRONCronos Group1.8602 of 5 stars$1.92-3.0%N/A-21.7%$739.98M$124.59M-14.77450Positive NewsREPLReplimune Group4.1461 of 5 stars$9.57+6.6%$19.75+106.4%+12.6%$737.72MN/A-3.12210High Trading VolumeIMTXImmatics2.2987 of 5 stars$6.01+11.5%$14.67+144.0%-53.9%$730.52M$144.15M-9.11260Analyst RevisionGap UpHigh Trading VolumeGYREGyre Therapeutics0.0814 of 5 stars$7.68-15.3%N/A-19.8%$720.06M$100.64M384.0040High Trading VolumeDAWNDay One Biopharmaceuticals1.6577 of 5 stars$7.01+9.9%$30.57+336.1%-44.1%$710.55M$161.92M-6.8160Positive NewsVIRVir Biotechnology3.0061 of 5 stars$5.07+2.6%$32.86+548.1%-51.7%$700.87M$14.30M-1.29580Positive NewsAVXLAnavex Life Sciences3.9187 of 5 stars$7.56+0.4%$44.00+482.0%+114.2%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.1661 of 5 stars$3.36flat$5.50+63.7%+13.1%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus3.9477 of 5 stars$9.97+8.5%$23.75+138.2%-13.6%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading Volume Related Companies and Tools Related Companies Intellia Therapeutics Competitors Cronos Group Competitors Replimune Group Competitors Immatics Competitors Gyre Therapeutics Competitors Day One Biopharmaceuticals Competitors Vir Biotechnology Competitors Anavex Life Sciences Competitors Arbutus Biopharma Competitors Evolus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
